LeonaBio reports Q2 2026 results, enrollment nears completion for ELAINE-3 trial
The company said it has enrolled 495 of an expected 600 patients in its Phase 3 lasofoxifene trial, with cash down to $51.1 million.
SEC filing
Latest
1 story
Sign inSign in1 story
The company said it has enrolled 495 of an expected 600 patients in its Phase 3 lasofoxifene trial, with cash down to $51.1 million.
SEC filing